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Summary
Objective: To examine whether urine concentrations of type II collagen neoepitope (uTIINE) distinguish subjects with progressive radiographic
and/or symptomatic knee osteoarthritis (OA) from those with stable disease.
Methods: Subjects were 120 obese middle-aged women with unilateral knee OA who participated in a 30-month randomized-controlled trial of
structure modiﬁcation with doxycycline, in which a standardized semiﬂexed anteroposterior view of the knee was obtained at baseline, 16
months and 30 months. Subjects were selected from a larger sample to permit a priori comparisons between 60 OA progressors and 60
nonprogressors, as deﬁned by joint space narrowing (JSN) in the medial tibiofemoral compartment. Each group contained 30 subjects
who exhibited clinically signiﬁcant increases in knee pain over 30 months and 30 who did not. Urine samples were obtained every 6 months
for determination of the creatinine (Cr)-adjusted uTIINE concentration.
Results: Baseline uTIINE levels were unrelated to JSN in the placebo group. However, among subjects in the active treatment group, a
1-standard deviation increment in baseline uTIINE (68 ng/mM Cr) was associated with a marginally signiﬁcant, two-fold increase in the
odds of progression of JSN (odds ratio 2.04, 95% conﬁdence interval 0.98e4.28). The within-subject mean of uTIINE values at baseline, 6
months and 12 months was associated with concurrent JSN measured at 16 months (0.10 mm of JSN per 69 ng/mM Cr, P¼ 0.008). Similar
results were seen in the interval between months 16 and 30 and in analyses using the maximum of intercurrent uTIINE levels.
Conclusion: Baseline uTIINE was not a consistent predictor of JSN in subjects with knee OA. However, serial measurements of uTIINE reﬂect
concurrent JSN.
ª 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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OA, an imbalance between synthesis and breakdown of the
extracellular matrix leads to the destruction and eventual
loss of articular cartilage, which results in restricted joint
movement, joint instability and pain. Current therapies, pri-
marily nonsteroidal anti-inﬂammatory drugs (NSAIDs) may
alleviate the mild to moderate pain and inﬂammation asso-
ciated with OA, but do not protect the articular cartilage and
have not demonstrated utility in modifying progression of
the disease. Therefore, agents that prevent the loss of joint
function, reduce tissue damage and decrease the need for
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need. Current research efforts target identiﬁcation of drug
candidates that can modify OA disease progression (i.e.,
disease-modifying osteoarthritis drugs; DMOADs). How-
ever, signiﬁcant gaps exist in our ability to clinically monitor
biological and structural changes in the joint that are
involved in the progression of OA. The discovery, develop-
ment and validation of appropriate biomarkers are key to
addressing these gaps.
In recent years, several molecular markers have been
developed and proposed as potential tools for identifying
OA patients with early disease and patients at risk of pro-
gression, as well as for monitoring OA progression and the
efﬁcacy of DMOADs. For example, the levels of type II
collagen C-telopeptide (CTX-II) and fragments of aggrecan
in synovial ﬂuid have been shown to increase soon after an-
terior cruciate ligament injury and meniscal tears in patients
with OA1. In these patients, markedly elevated levels of
both CTX-II and aggrecan fragments are observed in syno-
vial ﬂuid during the ﬁrst few weeks following injury, and then89
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comparison with preinjury levels. In addition, assays of
serum and urine from patients randomized to the placebo
group of recent clinical trials suggest that subjects with
higher baseline levels of serum cartilage oligomeric matrix
protein (COMP) or urine CTX-II exhibit a higher rate of
OA progression than those with lower levels of these
respective markers at baseline2e4. Moreover, combination
of markers for type II collagen synthesis and degradation
(plasma N-procollagen and urine CTX-II, respectively) in
an uncoupling index of cartilage turnover has been reported
to be more effective in predicting radiographic progression
of knee OA than measurement of either marker alone3,4.
Type II collagen is expressed almost exclusively in
articular cartilage, where it constitutes >90% of the total
protein. Cleavage and denaturation of type II collagen within
the cartilage constitute a hallmark of OA. Collagenases,
a subgroup of the matrix metalloproteinase (MMP) family
of proteases (e.g., MMP-1; MMP-8 and MMP-13), are
uniquely capable of cleaving the three identical alpha
chains that constitute the triple helical structure of type II
collagen ﬁbrils. This cleavage, which is the rate-limiting
step in degradation of the collagen ﬁbril, occurs at a unique
protease-sensitive site and results in the formation of a large
(3/4-length) amino-terminal fragment and a short (1/4-length)
carboxy-terminal fragment. An antibody, 9A4, has been
developed that recognizes the type II collagen neoepitope
(TIINE), GPPGPQG, generated at the new C-terminus on
the 3/4 fragment, but does not recognize this same
sequence within the intact molecule5. The initial collage-
nase cleavage is followed closely by proteolysis of the 3/4
fragment that results in the generation of TIINE-containing
fragments that are released from the cartilage into the
synovial space and are ultimately secreted in the urine
(Fig. 1). A liquid chromatographyemass spectrometry/mass
spectroscopy (LCeMS/MS) assay has been developed toquantify in urine 45-mer peptides, the most abundant
TIINE-containing peptides present in urine and synovial
ﬂuid6,7.
The 45-mer collagen type peptide is highly polar and
acidic (pI¼ 3.7), with a molecular weight of 4151 Da, and
hence passes through the glomerulus in a manner similar
to water. Because of its size and chemical properties, no
reabsorption into the plasma would be expected as it
passes through the kidney and it is undetectable in plasma
at the detection levels of the assay (0.169 ng/ml; 0.05 nM),
suggesting a high renal clearance rate.
In a recent cross-sectional study, the urinary concentra-
tion of TIINE (uTIINE) was shown to differentiate patients
with symptomatic OA of the hip or knee from those with
asymptomatic radiographic OA of these joints and from
age- and sex-matched controls8. We recently conducted
a 30-month randomized placebo-controlled trial (RCT) of
doxycycline in subjects with knee OA, in which the serial
radiographs used to measure joint space narrowing
(JSN) were obtained with a protocol that assured highly
reproducible parallel alignment of the medial tibial plateau
with the central x-ray beam, a criterion that has been
shown to yield a signiﬁcantly more rapid rate of JSN and
less between-subject variability in JSN than positioning
protocols that do not achieve alignment with high fre-
quency9. In that trial, doxycycline signiﬁcantly slowed the
progression of JSN at 16 months and 30 months and
reduced the frequency of clinically important increases in
knee pain10.
During the RCT, a sample of urine was obtained from
each subject at baseline and every 6 months thereafter.
Although a full biomarker analysis of all subjects in the
RCT was beyond the scope of the original investigation,
we conducted the pilot study described below to determine
whether a signal existed to suggest that baseline or
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Fig. 1. Generation of TIINE-containing peptides. Collagenases (MMP-1, -8, and -13) are uniquely capable of mediating the initial cleavage of
type II collagen at a speciﬁc intrahelical site to generate 3/4-length and 1⁄4 -length fragments. This cleavage generates a new C-terminus and
N-terminus ‘‘neoepitopes’’ on the 3/4 and 1⁄4 fragments, respectively. MMP-13 is also capable of further cleaving the 3/4-length fragment at
a position 45-aa upstream from the primary collagenase site, generating a neoepitope-containing 45-mer peptide that can be quantiﬁed in
urine by the LCeMS/MS TIINE assay.
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those with stable disease.
Methods
The procedures, beneﬁts, risks, and associated safe-
guards in this trial were approved by Institutional Review
Boards afﬁliated with each of the six participating clinical
research centers (see Acknowledgements).
SUBJECTS
Subjects were 120 women, 45e64 years of age, all of
whom had unilateral knee OA at baseline, based upon
Kellgren and Lawrence (K&L) criteria11, i.e., all exhibited
K&L grade 2 or 3 changes in the index knee and K&L grade
0 or 1 changes in the contralateral knee, and had completed
the 30-month RCT. All subjects were in the upper tertile of
the age-, race-, and sex-appropriate norms for body mass
index (BMI) established by the Second National Health
and Nutrition Examination Survey12.
PROCEDURES
Subjects for the biomarker analysis (N¼ 120) were
selected from the extremes of the distribution of 30-month
JSN values among all subjects who completed the doxycy-
cline trial per protocol (N¼ 307). This selection process per-
mitted comparisons of uTIINE levels between distinct
groups of OA progressors and nonprogressors. Sixty sub-
jects (21 doxycycline and 39 placebo) were chosen to
represent radiographic progressors, all of whom exhibited
JSN 0.33 mm in the index knee (meanSD¼ 0.97
0.75 mm), as determined by manual measurement of mag-
niﬁcation-corrected joint space width (JSW)13 in paired ﬂuo-
roscopically standardized semiﬂexed anteroposterior knee
radiographs14 taken at baseline and 30 months later. In
contrast, among the 60 radiographic nonprogressors
selected for this analysis (30 doxycycline, 30 placebo),
30-month JSN in the index knee was 0.22 mm (mean
SD¼0.03 0.17 mm, P < 0.0001).
Because most of the subjects enrolled in the RCT were
recruited from the community and were not patients who
had sought consultation for knee pain, baseline pain scores
were low, affording little opportunity for improvement, and
remained low in both treatment groups throughout the trial.
Nonetheless, progressor and nonprogressor groups were
constituted so as to contain 30 subjects (60 total) who
reported increases of 20% in 50-ft walk pain, relative to
their previous exam, with a minimum increase of 1 cm on
a 10-cm visual analog scale (VAS), on at least two of their
ﬁve semiannual pain assessments. The remainder (30 sub-
jects/group, 60 total) reported no increase in knee
pain 20% on any of their follow-up visits. All pain assess-
ments were conducted after a washout (ﬁve half-lives) of all
NSAIDs and analgesics taken by the subject.
Second morning-void urine samples were collected from
subjects at baseline of the doxycycline trial and every 6
months thereafter, immediately chilled at 4(C, clariﬁed by
centrifugation within 4 h, and then stored at 70(C until
thawed for assay.
uTIINE ASSAY
Quantitation of TIINE-containing 45-mer peptides with
5-hydroxyproline (HyP) was performed by two-dimensionalLCeMS/MS, utilizing an HP1100 high-performance liquid
chromatography (HPLC) system (Agilent, Palo Alto, CA)
composed of a quaternary pump, a CTC Analytics HTS
PAL autosampler (LEAP Technologies, Carrboro, NC),
and switching valve plumbed in-line with another HP1100
pump and interfaced to an API 4000 triple quadrupole
mass spectrometer (MDS-Sciex, Toronto, Canada)
operated in the positive ion electrospray and multiple-
reaction-monitoring modes. A 45-mer peptide containing
5-Hyp that was deuterated (d5) at the C-terminal glutamine
residue was used as an internal standard. For the immu-
noafﬁnity/reversed-phase LCeMS/MS analyses, urine sam-
ples diluted in 50 mM ammonium acetate, were injected
onto an immunoafﬁnity column prepared by cross-linking
5109 antibody, which speciﬁcally recognizes a unique
sequence of type II collagen (GEPGDDGPS, Fig. 1) adjacent
to the neoepitope on the 3/4-length fragment15, to protein
G-Poros material. The column was then washed for 3 min
with 50 mM NH4OAc, pH 7, at 1 ml/min, following which
the valve was switched and the captured peptides were
eluted off the immunoafﬁnity column with a 1% formic
acid solution onto a C-18 peptide macro trapping column
(Michrom BioResources, Auburn, CA) for another 3 min.
Peptides were then eluted off the trapping column onto
a 2.1 100 mm C-18 analytical column (Keystone Scien-
tiﬁc, Bellefonte, PA) with a 10 min gradient of 95% H2O,
1% HCOOH to 65% CH3CN, 1% HCOOH.
Selected 45-mer peptides in urine (referred to hereafter
as uTIINE) were speciﬁcally detected by monitoring HPLC
elution times and ion pairs corresponding to the parent
and speciﬁc fragment ion mass/charge values of 1038.8/
568.3 and 1040.3/573.3 for 45-mer TIINE and for its deuter-
ated internal standard, respectively. Analyte concentrations
were determined by comparing the LCeMS/MS peak areas
to that of deuterated internal standard. Standard analyte
curves were analyzed prior to, and following, assay of the
study samples to ensure equivalent instrument responses
for both the analyte and internal standard.
The LCeMS/MS assay was performed by Quest Pharma-
ceutical Services, LLC (Newark, DL). Concentrations of
uTIINE (ng/ml) were normalized for the urinary creatinine
(Cr) concentration (mM/ml), and the units reported for the
corrected uTIINE concentrations are ng/mM Cr.
Extensive validation studies were carried out with the
TIINE assay. Because every sample is assayed by triple
quadrupole mass spectrometry, the selectivity of the assay
is complete. The deuterium-labeled standard does not over-
lap with the analyte. By spiking in urine samples containing
0.886 ng/ml of TIINE, dilutional linearity was demonstrated
between the lower limit of quantitation (LLOQ, i.e.,
0.169 ng/ml) and 7.5 ng/ml. TIINE recovery from spiked
human urine was determined to be 98.1% (range
94.2e108.0%). The interassay precision, determined as
the coefﬁcient of variation, ranged from 4.0% to 8.7%,
increasing to 12.3% at the LLOQ. Inter-run accuracy ranged
from 0.6% to 2.7% relative error, with 14.2% at the LLOQ.
Stability of the analyte was demonstrated in urine samples
frozen for a year: in samples analyzed after storage for that
duration, the precision of measurements gave a coefﬁcient
of variation (CV) of 0.74e8.1% and an accuracy of
0.8e3.1% relative error, compared to the initial value.
STATISTICAL ANALYSIS
The predictive utility of baseline levels of uTIINE with
respect to radiographic and symptomatic progression of
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regression analyses. The analyses calculated the change in
odds of progression associated with a 1-standard deviation
(SD) increase in baseline uTIINE concentration. Odds ratios
(OR) were adjusted for baseline values of JSW and VAS
walk pain scores. The OR values for prediction of symptom-
atic progression were adjusted also for BMI. Separate anal-
yses were performed on data from the placebo group and
the active treatment group.
Repeated measures (mixed) models were used to deter-
mine whether variations in serial uTIINE levels reﬂected con-
current JSN in the index and contralateral knee. Using the
approach employed by Sharif et al.16, we computed
the within-subject mean and within-subject maximum of the
three uTIINE concentrations over each of the two discrete
intervals between radiographic examinations (i.e., the base-
line, 6-month and 12-month samples for the 0- to 16-month
interval; the 18-month, 24-month and 30-month samples for
the 16- to 30-month interval). Separate repeated measures
models were ﬁt with each candidate independent variable
(mean and maximum uTIINE concentrations) over each
interval (0e16 months, 16e30 months). Knee (index or con-
tralateral) was used as the repeated factor to account for
correlations within subject. Results (i.e., parameter esti-
mates) were adjusted for age, knee (index or contralateral)
and JSW at the start of the interval and were expressed as
the loss of JSW, in mm, associated with a 1-SD increase
in the mean or maximum of concurrent uTIINE concentra-
tions. Interactions of the uTIINE measure with knee and
treatment group were examined. When a signiﬁcant interac-
tion indicated a difference between subgroups with respect
to the association between uTIINE level and JSN, separate
models were ﬁt for each subgroup.
Even after omission of one outlying value (which was an
order of magnitude larger than the next largest value) from
the repeated measures analysis, the distributions of the
within-subject mean and maximum values for uTIINE
were not normally distributed. Accordingly, repeatedmeasures models were run on log-transformed uTIINE
data.
Results
The intra-assay reproducibility of uTIINE and Cr mea-
surements in 30 masked pairs of urine samples was
10.1% and 21.6%, respectively. After removal of one outlier
reproducibility was 9.5% and 4.0%, respectively.
Subjects selected for this study were, on average, 54.8
years old and had a mean BMI of 36.5 kg/m2. Radiographic
progressors and nonprogressors in both treatment groups
did not differ at baseline with respect to mean age and
BMI (Table I). However, the mean baseline JSW in the
index knee of radiographic progressors in the doxycycline
group was smaller than that in radiographic nonprogressors
(P < 0.05). Symptomatic progressors and nonprogressors
were similar at baseline with respect to age, uTIINE and
JSW. However, mean BMI among symptomatic progres-
sors in the placebo group was signiﬁcantly greater than
that among symptomatic nonprogressors (P < 0.05).
Accordingly, OR values for the prediction of progression
of knee pain were adjusted also for baseline BMI.
Among subjects in the doxycycline group, the mean of
baseline uTIINE concentrations of radiographic progressors
was 47% higher than that among radiographic nonprogres-
sors (P < 0.05) and 32% higher than that of radiographic
progressors in the placebo group (P < 0.10).
The criteria we employed to select subjects for this study
assured that the mean rate of JSN over 30 months among
radiographic progressors would be greater than that among
nonprogressors (P < 0.0001) (Table I). Likewise, the fre-
quency with which symptomatic progressors reported an
increase of 20% in 50-ft walk pain (minimum increa-
se¼ 1 cm) over successive semiannual pain assessments
was signiﬁcantly greater than that reported by symptomatic
nonprogressors (P < 0.0001).Table I
Baseline characteristics of progressors and nonprogressors by treatment group
Radiographic progression Symptomatic progression
Yes No Yes No
Placebo group (N¼ 69)
Number of subjects 39 30 36 33
Age, years (meanSD) 54.9 5.9 55.4 5.3 54.7 5.8 55.7 5.4
BMI, kg/m2 (meanSD) 36.6 6.8 37.0 5.4 38.4 6.0z 35.0 6.0z
uTIINE, ng/mM Cr (meanSD) 101.6 57.8 121.6 71.2 103.1 50.2 118.1 76.7
Minimum JSW, mm (meanSD)* 3.51 1.34 3.56 1.21 3.70 1.34 3.35 1.19
30-month JSN, mm (meanSD)* 1.04 0.90y 0.001 0.15y 0.69 1.01 0.48 0.65
Frequency of pain increases 20%,
relative to previous visit, % of ﬁve
semiannual assessments (meanSD)
24 23 22 23 44 8y 0 0y
Doxycycline group (N¼ 51)
Number of subjects 21 30 24 27
Age, years (meanSD) 55.6 5.0 53.4 5.77 54.2 5.5 54.4 5.6
BMI, kg/m2 (meanSD) 36.7 6.4 35.6 5.9 36.6 6.9 35.6 5.4
uTIINE, ng/mM Cr (meanSD) 134.3 89.8y 91.1 40.8y 108.0 67.5 110.0 70.1
Minimum JSW, mm (meanSD)* 3.26 1.39z 4.01 1.08z 3.80 1.36 3.61 1.19
30-month JSN, mm (meanSD)* 0.83 0.31y 0.07 0.18y 0.28 0.56 0.32 0.46
Frequency of pain increases 20%,
relative to previous visit, % of ﬁve
semiannual assessments (meanSD)
21 26 23 24 47 10y 0 0y
yP < 0.0001 for comparison of progressors and non-progressors. zP < 0.05 for comparison of progressors and non-progressors.
*Index knee.
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OR values for the prediction of progression of JSW and
knee pain are presented in Table II. In subjects from the pla-
cebo group, after adjustment for baseline JSW and knee
pain, the odds of progression of JSN were unrelated to
the baseline uTIINE concentration (OR 0.74 per 64 ng/mM
Cr, P¼ 0.242). In contrast, the odds of progression of
JSN in the doxycycline group were increased two-fold for
every 64.2 ng/mM Cr increase in the baseline uTIINE con-
centration (adjusted OR 2.04 per 68 ng/mM Cr). However,
the association was only marginally signiﬁcant (P¼ 0.058).
After additional control for BMI, logistic regression analy-
ses did not yield evidence that the baseline uTIINE concen-
tration predicted progression of knee pain in either the
placebo group (OR 0.76 per 64 ng/mM Cr, P¼ 0.216) or
the doxycycline treatment group (OR 0.80 per 68 ng/mM
Cr, P¼ 0.485).
ASSOCIATION BETWEEN SERIAL uTIINE CONCENTRATIONS
AND CONCURRENT JSN
The correlation between the within-subject mean of the
uTIINE values obtained over the 0- to 16-month interval
and that of the values obtained during the 16- to 30-month
interval was þ0.67. The correlation between maximum
uTIINE values in the two intervals was þ0.59. The results
of the mixed models evaluating the association between se-
rial uTIINE levels and concurrent JSN are shown in Table III.
During the initial 16 months between radiographic exam-
inations (i.e., baseline to 16 months), the within-subject
Table II
Adjusted OR values from multiple logistic regression analyses to
distinguish subjects who exhibited progression of 30-month JSN
and knee pain from those who did not on the basis of the baseline
concentration of uTIINE
Outcome Placebo group (N¼ 69)
baseline uTIINE
SD¼ 64 ng/mM Cr
Doxycycline group
(N¼ 51) baseline uTIINE
SD¼ 68 ng/mM Cr
OR* 95% CI OR* 95% CI
JSN 0.74 0.44e1.23 2.04 0.98e4.28
Knee pain 0.71 0.41e1.23 0.80 0.43e1.50
*Change in odds of progression of JSN per 1-SD increase in the
baseline uTIINE concentration, adjusted for baseline JSW and
baseline VAS score for 50-ft walk pain. OR values for prediction
of knee pain were adjusted also for baseline BMI.mean of uTIINE values obtained at baseline, 6 months
and 12 months was directly related to concurrent JSN.
For each 69 ng/mM Cr (1 SD) difference between subjects
in mean uTIINE level over this interval, concurrent JSN in-
creased 0.10 mm (P¼ 0.008). A 1-SD difference in the
within-subject maximum of the intercurrent uTIINE concen-
trations was associated with a slightly larger increase in
JSN (b¼ 0.14 mm/108 ng/mM Cr).
An association between uTIINE and JSN also was seen
during the ensuing 14-month interval (i.e., between month
16 and month 30 of the original doxycycline trial). In the
analyses of mean uTIINE values, a signiﬁcant interaction
was found between mean uTIINE and treatment group
(P¼ 0.030). In separate analyses, the association between
mean uTIINE and JSN was seen only in the placebo group
(b¼ 0.17 mm/ng/mM Cr, P¼ 0.004). The association
between the maximum uTIINE value over months 18, 24
and 30 and JSN over that same interval was signiﬁcant in
data from combined treatment groups (b¼ 0.10 mm/98
ng/mM Cr, P¼ 0.011).
Discussion
The recent development of a novel LCeMS/MS assay to
quantify collagenase-generated 45-mer neoepitope-con-
taining peptides in urine has led to investigations of whether
the uTIINE concentration may be an indicator of articular
cartilage degradation that can serve as a useful biomarker
of imminent progression of OA. A previous cross-sectional
analysis showed that the mean uTIINE concentration in
subjects with symptomatic OA of the knee or hip was
>47% higher than that in subjects with asymptomatic OA
(P¼ 0.007) and 97% greater than that in age- and sex-
matched controls (P¼ 0.001)8. The mean uTIINE values
in the various comparison groups of our previous cross-sec-
tional study were consistent with the baseline means found
in the progressors and nonprogressors in the present study.
This study was designed to ascertain whether baseline and
serial uTIINE concentrations could distinguish subjects with
progressive radiographic or symptomatic OA from those
with stable disease.
The results of this study provide evidence that uTIINE
levels reﬂect concurrent progression of JSN in the knee
radiograph. In analyses covering two discrete time intervals
(i.e., baseline to month 16, month 16 to month 30), both the
mean and maximum intercurrent uTIINE concentrations
were directly associated with the rate of JSN (Table III).
The magnitude of parameter estimates from the mixed
models indicated that, for any two subjects who differedTable III
Parameter estimates (b) from mixed models to predict radiographic JSN between baseline and 16 months and between 16 months and 30
months, based upon intercurrent concentrations of uTIINE
Intercurrent uTIINE value 0- to 16-month interval 16- to 30-month interval
SD, ng/mM Cr b, mm/SD of uTIINE* SD, ng/mM Cr b, mm/SD of uTIINE*
Mean 69 0.10y 66 0.17y,z
Maximum 108 0.14y 98 0.10x
*Change in JSN, in mm, associated with a 1-SD increase in mean or maximum uTIINE concentration (ng/mM Cr) after adjustment for age,
knee and JSW at the start of the interval.
yP< 0.01.
zA signiﬁcant uTIINE by treatment group interaction was detected (P< 0.05). The entry represents the association between mean uTIINE
levels and JSN in the placebo group only.
xP< 0.05.
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semiannual uTIINE values, the subject with the higher
mean could be expected to exhibit 0.10e0.17 mm greater
JSN concurrently than the subject with the lower value, after
adjustment for age, knee and JSW at the start of the inter-
val. This range of values for excess JSN predicted by inter-
current uTIINE values encompasses the values for mean
annual loss of medial JSW reported in many epidemiologic
studies of JSN and in previous clinical trials of purported
disease-modifying OA drugs17,18.
In contrast to the concurrent validity of serial uTIINE con-
centrations, the evidence for predictive validity of the base-
line concentration varied by treatment group. Higher levels
of baseline uTIINE tended to decrease the odds of progres-
sion of JSN in subjects in the placebo group (Table II),
whereas a marginally signiﬁcant (P¼ 0.058) direct associa-
tion between uTIINE and JSN was seen in the active treat-
ment group. This discrepancy was not due to the lack of
a normal distribution of log-transformed baseline uTIINE
values insofar as similar results were seen in analyses of
baseline uTIINE values by tertile (data not shown). The rea-
sons for this discrepancy are not clear. However, the pres-
ent results are consistent with pilot studies of other markers
of type II collagen degradation in this sample (urinary CTX-II
and plasma C2C), the baseline values of which also failed
to predict JSN in the placebo group19,20.
The present results do not support those from biomarker
analyses in other samples suggesting the predictive validity
of markers of cartilage and type II collagen degradation
(serum COMP and urinary CTX-II) for radiographic progres-
sion of OA2e4. In the placebo group of a 3 year knee RCT,
patients who progressed by two K&L grades of radiographic
severity had signiﬁcantly higher serum COMP levels at
baseline and at study end, while COMP levels did not cor-
relate with changes in the Lequesne index or Western On-
tario and McMaster Universities (WOMAC) OA Index pain
and functional limitation scores2. Similarly, in the large pop-
ulation-based Rotterdam cohort, subjects with urinary CTX-
II levels in the highest quartile at baseline had a six-fold
increased risk for progression of JSN at the knee and an
8.4-fold increased risk for progression of JSN at the hip4.
Finally, in a subset of subjects with knee OA in an RCT, in-
creased baseline values in the uncoupling index of serum
levels of N-propeptide of type IIA procollagen (PIIANP)
and urinary CTX-II (i.e., markers of type II collagen synthe-
sis and degradation, respectively) were reported to be asso-
ciated with greater progression of JSN3.
Approximately 15 years ago, we reviewed a variety of sci-
entiﬁc and clinical issues that may confound the interpreta-
tion, and affect the utility, of biomarker measurements in
OA21. Among the issues we raised at that time were the
absence of controls for sources of molecular markers other
than the index joint (e.g., articular cartilage in other joints,
nonarticular cartilage) and the limitations of conventional
radiography to detect progression of OA. The protocol for
ﬂuoroscopically standardized knee radiography used in the
present study effectively eliminates longitudinal changes in
the appearance of the joint space caused by variations in
positioning of the knee or changes in knee pain13,22 and,
therefore, represents an important scientiﬁc advance over
the conventional weight-bearing extended knee view that
was commonly used 15 years ago. However, extraneous
sources of variation in molecular marker levels continue to
confound this and other biomarker studies. Nonetheless,
the present pilot study showed that serial uTIINE concentra-
tions could distinguish subjects who were selected a priori to
represent radiographic progressors and nonprogressors.We cannot say on the basis of this pilot study whether
uTIINE can serve as a useful surrogate for radiographic out-
comes in OA. Such a demonstration would require the anal-
ysis of samples from all subjects in the doxycycline trial,
who exhibited the full spectrum of progressive changes of
OA e not only those from the extremes of the distribution
of JSN. More important, a deﬁnitive demonstration of surro-
gacy must be performed in a sample that accurately repre-
sents the structure-modifying effect of doxycycline seen in
the full sample of the trial12. That possibility was negated
by the stratiﬁed selection process used in the present study.
However, the present data provide a signal that, despite the
clinical limitations inherent in all OA biomarker studies21,
variations in serial uTIINE may reﬂect progression of knee
OA. Finally, it may be that no single biomarker is sensitive
enough to serve as a surrogate for radiographic outcomes
in OA, but that the combination of multiple biomarkers, rep-
resenting different aspects of articular cartilage biochemis-
try, may signiﬁcantly improve the detection and prediction
of radiographic changes of knee OA.
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